SVB Securities analyst Daina Graybosch reiterated a Buy rating on Compugen (CGEN – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $0.79.
Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, 2seventy bio, and Compugen. According to TipRanks, Graybosch has an average return of -22.7% and a 27.75% success rate on recommended stocks.
Compugen has an analyst consensus of Moderate Buy, with a price target consensus of $5.50, implying a 596.03% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
CGEN market cap is currently $64.57M and has a P/E ratio of -1.95.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Read More on CGEN:
